Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Propiomazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 6/20 | 1.00 |
| ▸ | HTR1A | P08908 | 6/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 6/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 6/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 6/20 | 1.00 |
| ▸ | DRD3 | P35462 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | DRD2 | P14416 | 3/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.66 |
| ▸ | MTOR | P42345 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R)-Propiomazine SCHEMBL6910697 | 1.00 | CHRM2 (1.00) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| Propiomazine SCHEMBL93770 | 1.00 | CHRM2 (1.00) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| Propiomazine SCHEMBL29609596 | 1.00 | CHRM2 (1.00) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| Propiomazine SCHEMBL30903904 | 0.99 | CHRM2 (0.98) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| Propiomazine SCHEMBL141677 | 0.99 | CHRM2 (0.98) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| Propiomazine SCHEMBL6372719 | 0.99 | CHRM2 (0.98) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| Propiomazine SCHEMBL720224 | 0.98 | CHRM2 (0.96) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| Propiomazine SCHEMBL3863991 | 0.94 | CHRM2 (0.88) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| SCHEMBL10368273 | 0.88 | CHRM2 (0.79) | CHRM2HTR1ACHRM1ADRA1AOPRM1 | |
| Aceprometazine SCHEMBL142393 | 0.88 | HTR1A (0.79) | CHRM2HTR1ACHRM1ADRA1AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4154879-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NICOTINE WITHDRAWAL SYMPTOMS | KOREA INST SCI & TECH (KR) | 2025-09-10 | — | — | EP | claimed |
| US-12324435-B2 | Combination of novel nitrification inhibitors and herbicides as well as combination of (thio)phosphoric acid triamides and herbicides | BASF SE (DE) | 2025-06-10 | — | — | US | disclosed |
| US-20230072164-A1 | GRANULAR PHARMACEUTICAL PRODUCT FOR ORAL ADMINISTRATION FROM A PRE-FILLED STRAW AND METHOD OF MANUFACTURING SUCH PHARMACEUTICAL PRODUCT | ALTERNO LABS D.O.O. (SI) | 2023-03-09 | — | — | US | disclosed |
| EP-4096642-A1 | GRANULAR PHARMACEUTICAL PRODUCT FOR ORAL ADMINISTRATION FROM A PRE-FILLED STRAW AND METHOD OF MANUFACTURING SUCH PHARMACEUTICAL PRODUCT | Alterno Labs d.o.o. (SI) | 2022-12-07 | — | — | EP | disclosed |
| US-20220117231-A1 | Combination of Novel Nitrification Inhibitors and Herbicides as Well as Combination of (Thio)Phosphoric Acid Triamides and Herbicides | BASF SE (DE) | 2022-04-21 | — | — | US | disclosed |
| WO-2022023960-A1 | METHODS OF TREATING AND PREVENTING CORONAVIRUS INFECTION AND DISRUPTING CORONAVIRUS REPLICATION | FUNDACIÓN UNIVERSITARIA SAN ANTONIO (UCAM) (ES) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12324435-B2 | Combination of novel nitrification inhibitors and herbicides as well as combination of (thio)phosphoric acid triamides and herbicides | NMT2, NAPRT, NAMPT | HRH1 3159/4885CHRM2 2527/4885HTR1A 3202/4885 |
| US-20220117231-A1 | Combination of Novel Nitrification Inhibitors and Herbicides as Well as Combination of (Thio)Phosphoric Acid Triamides and Herbicides | NMT2, NAPRT, NAMPT | HRH1 3159/4885CHRM2 2527/4885HTR1A 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.